PH12014501814A1 - Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for treating overactive bladder - Google Patents

Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for treating overactive bladder

Info

Publication number
PH12014501814A1
PH12014501814A1 PH12014501814A PH12014501814A PH12014501814A1 PH 12014501814 A1 PH12014501814 A1 PH 12014501814A1 PH 12014501814 A PH12014501814 A PH 12014501814A PH 12014501814 A PH12014501814 A PH 12014501814A PH 12014501814 A1 PH12014501814 A1 PH 12014501814A1
Authority
PH
Philippines
Prior art keywords
beta
overactive bladder
combination
muscarinic receptor
receptor antagonists
Prior art date
Application number
PH12014501814A
Inventor
Caltabiano Stephen
Ohlstein Eliot
Mccallum Stewart
Original Assignee
Altherx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altherx Inc filed Critical Altherx Inc
Publication of PH12014501814A1 publication Critical patent/PH12014501814A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.
PH12014501814A 2012-02-09 2014-08-11 Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for treating overactive bladder PH12014501814A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261596893P 2012-02-09 2012-02-09
PCT/US2013/025285 WO2013119910A1 (en) 2012-02-09 2013-02-08 Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder

Publications (1)

Publication Number Publication Date
PH12014501814A1 true PH12014501814A1 (en) 2014-11-24

Family

ID=48948043

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014501814A PH12014501814A1 (en) 2012-02-09 2014-08-11 Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for treating overactive bladder

Country Status (13)

Country Link
EP (1) EP2811989A1 (en)
JP (1) JP2015509931A (en)
KR (1) KR20150020160A (en)
CN (1) CN104684549A (en)
AR (1) AR089957A1 (en)
AU (1) AU2013216864A1 (en)
CA (1) CA2864173A1 (en)
HK (1) HK1204966A1 (en)
IL (1) IL234033A0 (en)
PH (1) PH12014501814A1 (en)
SG (1) SG11201404776PA (en)
TW (1) TW201338772A (en)
WO (1) WO2013119910A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
DK3365321T3 (en) 2015-10-23 2024-01-15 B3Ar Therapeutics Inc SOLABEGRON-ZWITTERION AND USES THEREOF
KR101868438B1 (en) 2017-04-13 2018-06-20 (주) 성운파마코피아 Method for preparing amide derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (en) 1960-07-26
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
AU2008233232A1 (en) * 2007-03-29 2008-10-09 Merck Sharp & Dohme Corp. Combination therapy for the treatment-of lower urinary tract symptoms
PE20091825A1 (en) 2008-04-04 2009-12-04 Merck & Co Inc HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR
US8354403B2 (en) 2009-08-27 2013-01-15 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
EP2485595A4 (en) * 2009-10-07 2014-03-12 Merck Sharp & Dohme Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent

Also Published As

Publication number Publication date
EP2811989A1 (en) 2014-12-17
AR089957A1 (en) 2014-10-01
SG11201404776PA (en) 2014-09-26
HK1204966A1 (en) 2015-12-11
JP2015509931A (en) 2015-04-02
CA2864173A1 (en) 2013-08-15
TW201338772A (en) 2013-10-01
CN104684549A (en) 2015-06-03
IL234033A0 (en) 2014-09-30
WO2013119910A1 (en) 2013-08-15
AU2013216864A1 (en) 2014-09-11
KR20150020160A (en) 2015-02-25

Similar Documents

Publication Publication Date Title
MX353105B (en) Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder.
MX2016007965A (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists.
MX2017006320A (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists.
PH12014501814A1 (en) Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for treating overactive bladder
PH12015501247A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
SG195375A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX2016001030A (en) Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist.
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3463312A4 (en) Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
EA201490938A1 (en) SPIROTHYENE-PYRANIPIPERIDINE DERIVATIVES AS ANTAGONISTS OF ORL-1 RECEPTOR FOR USE TO TREAT ALCOHOL DEPENDENCE AND ABUSE OF ALCOHOL
MX2017015047A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity.
MX2015012043A (en) Muscarinic agonists.
PH12016500044B1 (en) Vasopressin-2 receptor agonists
MX2014014813A (en) Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders.
UA96048C2 (en) Use of interleukin-1 receptor antagonist as an frigoprotective agent
UA96037C2 (en) Use of interleukin-1 receptor antagonist as an antialcoholic agent